Xiaobin Wu Sells 1,484 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,484 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer owned 40 shares in the company, valued at $10,774.80. This trade represents a 97.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 1.7%

NASDAQ ONC traded down $4.56 during trading hours on Wednesday, hitting $263.61. 291,079 shares of the company’s stock were exchanged, compared to its average volume of 255,249. The business’s 50 day moving average is $301.03 and its 200-day moving average is $315.60. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $239.25 and a 12-month high of $385.22. The firm has a market capitalization of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

ONC has been the topic of a number of research reports. Royal Bank Of Canada raised their price objective on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Wolfe Research initiated coverage on BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective on the stock. Morgan Stanley restated an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Finally, Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds have recently modified their holdings of ONC. EFG International AG purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at about $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $35,000. CWM LLC raised its holdings in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at about $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.